Boston Scientific Second Quarter Results Exceed Consensus Sales and EPS; Full-Year Guida... (in some cases have affected and in the f...)

Boston Scientific Second Quarter Results Exceed Consensus Sales and EPS; Full-Year Guidance Raised

Date:7/28/2011

in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.
As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: future political, environmental, economic, competitive, reimbursement, legal and regulatory conditions; new product introductions and the market acceptance of those products; the market for our products, including the U.S. CRM market; expected pricing environment; expected procedural volumes; clinical trial results; demographic trends; intellectual property rights and related and other litigation; financial market conditions; the effect of our goodwill impairment charges and our restructuring initiatives; integration of acquired companies; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.
We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-look
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Related medicine technology :

1. Boston Scientific Announces Five-Year, $150 Million Investment in China to Accelerate Commercial Expansion
2. Boston Scientific to Webcast Conference Call Discussing Second Quarter 2011 Financial Results
3. Boston Scientific Completes Clinical Trial Enrollment for Adapt™ Monorail™ Carotid Stent System
4. Boston Scientific Announces U.S. and European Launch of Interlock™ - 35 Fibered IDC™ Occlusion System
5. Boston Scientific Welcomes Passage of Patent Reform Bill
6. Boston Scientific to Donate $1 Million to ASGEs IT & T Capital Campaign to Build a New State-of-the-Art GI Training Center
7. Boston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter
8. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J&J Patents
9. Boston Scientific Announces Voluntary Recall of iCross™ Coronary Imaging Catheters
10. Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System
11. Boston Heart Lab Changes Name to Boston Heart Diagnostics

Post Your Comments:

(Date:6/17/2013)... Perrigo Company (NYSE: PRGO ; ... agreement to acquire and has completed the acquisition of ... Fera Pharmaceuticals, LLC and its affiliates (Fera), a privately-held, ... pharmaceutical company. The acquired portfolio, including nine prescription ANDA ... during calendar year 2012. Terms of the transaction include ...

(Date:6/17/2013)... , June 17, 2013 AbbVie (NYSE: ... from a Phase I study of ABT-199/GDC-0199, an ... patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL), ... High-risk CLL patients are those with deletions of ... fludarabine therapy. These data were presented at the ...

(Date:6/17/2013)... -- Life Technologies Corporation (NASDAQ: LIFE ... iPSC Reprogramming Vectors , the world,s first product to ... developers a Nobel Prize in 2012 for the ability ... embryonic state. Scientists use induced pluripotent stem ... somatic cells. The iPSCs can then be differentiated into ...

Breaking Medicine Technology:Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million 2 Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million 3 AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting 2 AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting 3 AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting 4 AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting 5 AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting 6 Life Technologies Expands Range of Stem Cell Reprogramming Solutions 2 Life Technologies Expands Range of Stem Cell Reprogramming Solutions 3

[0] Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million [0] AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting [0] Life Technologies Expands Range of Stem Cell Reprogramming Solutions

... " Two Years and Counting " White Paper ... Milestones and Educational Needs Elsevier ... more than 1,300 healthcare organizations, today announced the addition of a ... its eBook, A Guide to Education and Training for ICD-10 ...

... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... discovering breakthrough treatments for human disease, announced positive, ... 2 study in carcinoid syndrome with LX1032 ... condition caused by neuroendocrine tumors that usually originate ...

Cached Medicine Technology:Elsevier / MC Strategies Introduces Additional Resources to its ICD-10 Roadmap, Helping Healthcare Organizations Prepare for October 2013 2 Elsevier / MC Strategies Introduces Additional Resources to its ICD-10 Roadmap, Helping Healthcare Organizations Prepare for October 2013 3 Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 2 Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 3 Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 4 Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 5

Elsevier / MC Strategies Introduces Additional Resources to its ICD-10 Roadmap, Helping Healthcare Organizations Prepare for October 2013 Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome

(Date:6/17/2013)... New York (PRWEB) June 18, 2013 ... has more physicians listed in New York magazine's ... In the latest survey, 209 NewYork-Presbyterian physicians from ... fortunate to have some of the nation's best ... J. Corwin, CEO of NewYork-Presbyterian Hospital. "We are ...

(Date:6/17/2013)... and Drug Administration (FDA) imposes new graphic warning ... First Amendment challenge if they depict health consequences ... evidence, says a Georgetown University Medical Center public ... warning labelswhich combine images with health warningsare a ... other countries, but the tobacco industry argues they ...

(Date:6/17/2013)... MA (PRWEB) June 17, 2013 Daimer ... robust steam cleaner equipment , such as expertly designed ... launched the KleenJet® Pro Plus 200S for apartment dwellers ... up to 310°F in 15 minutes and pressure levels ... effectively. The machine can be used to clean carpet ...

(Date:6/17/2013)... Bust’DD (pronounced ‘busted’), a new company that ... women with large busts, will soon launch their crowdfunding campaign ... understand the problem of ill-fitting bras and want to offer ... is to raise at least $25,000 to create their beta ... on a wide scale. , In order to kick off ...

(Date:6/17/2013)... (PRWEB) June 17, 2013 Today, ... stand-alone HRAs for small businesses . Zane Benefits, ... employer sponsored health benefits, is the leader in ... arrangements . , According to Zane Benefits’ website, ... Accounts or HRAs, offer small businesses an affordable ...

Breaking Medicine News(10 mins):Health News:NewYork-Presbyterian Leads NY Metro Area Hospitals on New York Magazine's Annual ‘Best Doctors' List 2 Health News:Can new FDA graphic warning labels for tobacco pass a first amendment legal challenge? 2 Health News:Daimer Ships Vapor Steam Cleaner For Homeowners 2 Health News:Daimer Ships Vapor Steam Cleaner For Homeowners 3 Health News:Arizona Startup Bust’DD Looking to Start a BRAvolution 2 Health News:Arizona Startup Bust’DD Looking to Start a BRAvolution 3 Health News:Zane Benefits Publishes New Information on Stand-Alone HRAs for Small Businesses 2

[0] NewYork-Presbyterian Leads NY Metro Area Hospitals on New York Magazine's Annual ‘Best Doctors' List [0] Can new FDA graphic warning labels for tobacco pass a first amendment legal challenge?[0] Daimer Ships Vapor Steam Cleaner For Homeowners [0] Arizona Startup Bust’DD Looking to Start a BRAvolution [0] Zane Benefits Publishes New Information on Stand-Alone HRAs for Small Businesses

... , , , ... , the global leader in thin computing and client virtualization, today announced ... Smiles is a rapidly-growing company whose mission is to bring quality dental ... first office in 2002 in Atlanta, GA, the network has demonstrated substantial ...

... , , , ... Health, Inc. (Nasdaq: GHDX ) today announced that Kim ... Adams 29th Annual Global Growth Conference in Boston, on Thursday, August ... access the live and subsequently archived webcast of the presentation, visit ...

... , , , ... Aug. 6 CSC (NYSE: CSC ... company as a preferred provider to help member hospitals comply with the ... U.S. federal government stimulus package. Under the ARRA, hospitals will receive incentive ...

... TAMPA, Fla., Aug. 6 Gold Standard/Elsevier ... of three MedCounselor consumer drug information modules for pharmacies and ... to take medications safely, assists in identifying unknown tablets or ... indispensable in helping to increase consumer compliance to their drug ...

... , KIBBUTZ SHAMIR, Israel, Aug. 6 Shamir ... to issue its second quarter of 2009 earnings results on Thursday, August ... at 11:00 A.M. EDT that morning. , , ... listen live, please go to www.kcsa.com approximately five ...

... Va., Aug. 6 Sunrise Senior Living, Inc. (NYSE: ... second quarter of 2009. Sunrise will host a conference call ... discuss the financial results. , , "Our restructuring ... expense controls. In recent weeks we have seen a modest lift ...

Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs)Genomic Health to Present at Canaccord Adams 29th Annual Global Growth Conference CSC to Help Georgia Hospital Association Members Achieve 'Meaningful Use' of Electronic Health Records Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules Shamir Optical Industry Ltd. to Host Conference Call Announcing Second Quarter of 2009 Earnings Results Sunrise Reports Financial Results for Second-Quarter 2009

... product line has the right product for ... and from intubated patients to patients with ... both anesthesia and critical care applications., ... protection for patients and staff members. This ...

Bacterial/Viral Filters for Anesthesia and Respiratory Applications...

Medicine Products:

Medisize Ulti-Mist Filter 30303 Filter 5096 Filter 303HEPA Filter